Filing Flows › Lineage Cell Therapeutics (LCTX) › Q1 2026
Lineage Cell Therapeutics (LCTX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Lineage Cell Therapeutics (LCTX) reported revenue of $1.7M for the first quarter 2026 (Q1 2026), +15% from a year earlier and -74% from the quarter before. Operating margin was -440.2%, net loss $4.8M (277.6% of revenue).
Lineage Cell Therapeutics, Q1 2026: revenue $1.7M (+15% year over year), operating margin -440.2%, net loss $4.8M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -74% | +15% |
| Operating profit | −$7.6M | — | — |
| Net earnings | −$4.8M | -637% | — |
| Operating cash flow | −$8.1M | — | — |
What changed
Revenue was $1.7M in Q1 2026, up 15% year over year and down 74% from the previous quarter. Upfront License Fees was the largest line at 50% of revenue. Royalties License and Other Revenues declined 35%.
Operating costs exceeded revenue by $7.6M, an operating margin of -440.2%. Total costs grew 16% against revenue growth of 15%. The fastest-growing cost line was Research & development (+36%). The quarter ended with a net loss of $4.8M, after a profit of $892K the previous quarter. Non-operating items added $2.8M, -59% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$8.1M. Non-cash charges added back $188K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $55K exceeded it, leaving free cash flow of −$8.1M.
Questions
What was Lineage Cell Therapeutics' revenue in the first quarter 2026?
Lineage Cell Therapeutics (LCTX) reported revenue of $1.7M for the first quarter 2026 (Q1 2026), +15% from a year earlier and -74% from the quarter before.
Was Lineage Cell Therapeutics profitable in the first quarter 2026?
Operating loss was $7.6M (-440.2% of revenue) and net loss $4.8M.